Targeted Oncology

📢 More Friday FDA news: The FDA has authorized expanded access to daraxonrasib for metastatic pancreatic cancer. This decision comes after phase 3 data from the RASolute 302 trial showed major survival gains over chemotherapy, reducing the risk of death by 60%, and manageable safety. 🔗 Get the full details of the decision: https://lnkd.in/egUm2FYa #PancreaticCancer #PDAC #FDANews

📢 BREAKING: The #FDA has approved vepdegestrant, the first PROTAC in any indication, for ESR1-mutated ER+/HER2– advanced breast cancer. Phase 3 VERITAC-2 data demonstrated a PFS benefit (HR, 0.57) in the ESR1-mutated subgroup vs fulvestrant with a generally manageable safety profile, supporting its role in this molecularly defined population. 🔗 Explore the data and implications here: https://lnkd.in/eV9MekUe #FDANews #BreastCancer

Another month of continued regulatory momentum has passed. To keep you up to date, we’ve rounded up the key FDA oncology approvals, NDAs, and priority reviews shaping the treatment landscape this April. 🔎 ⭐ Get the full details on each decision in our latest article (free sign-up required): https://lnkd.in/dxKvNfzE #FDA #Oncology #CancerResearch #DrugDevelopment

Coming soon 🎥 In our upcoming Evolving Paradigms in Oncology video series, Ticiana Leal, MD from Winship Cancer Institute of Emory University and Wade Iams, MD, MSCI from Tennessee Oncology take a closer look at Lambert-Eaton Myasthenic Syndrome (LEMS) in small cell lung cancer. This conversation focuses on: ✔️ Improving recognition in complex clinical settings ✔️ Navigating diagnostic uncertainty ✔️ Managing paraneoplastic syndromes to support patient quality of life Stay tuned for the full discussion. #Oncology #SCLC #LungCancer #OncologyEducation

🔬 Emerging data in advanced ovarian cancer highlight the potential of IMNN-001, an investigational intraperitoneal IL-12 plasmid-based immunotherapy. In a recent discussion, Dr Premal H. Thaker (Washington University School of Medicine in St. Louis) reviewed findings suggesting a signal for OS benefit, particularly in patients with suboptimal responses to standard approaches. The mechanism—localized cytokine expression driving both innate and adaptive immune activation—continues to draw interest as a strategy to modulate the TME. With phase 3 evaluation underway, key questions remain around patient selection, durability of response, and integration with existing SOC (including chemotherapy and maintenance strategies). 🔗 Read the full interview: https://lnkd.in/e9YuT2kE #OvarianCancer #GynOnc #Immunotherapy

🌟 Physician in Focus: Manojkumar Bupathi, MD, MS We’re proud to spotlight Manoj Bupathi, medical oncologist and president of Rocky Mountain Cancer Centers, a practice in The US Oncology Network, and GU research co-chair at Sarah Cannon Research Institute. Bupathi was drawn to medicine at the intersection of science, problem-solving, and human connection. For him, oncology is not only about treating disease, but also about supporting patients and families through some of their most challenging moments. A key lesson from his career is the importance of teamwork in medicine. The best patient care happens when multidisciplinary expertise comes together with one shared goal: Doing what is best for the patient. Join us in celebrating our latest Physician in Focus. #PhysicianInFocus #OncologyLeadership #OncologyCommunity 

Catch up with the oncology news you missed from this week with the latest edition of The Targeted Pulse!

In this exclusive interview, we sit down with Dr Sikander Ailawadhi of the Mayo Clinic to discuss the recent positive CHMP opinion on subcutaneous isatuximab (Sarclisa) administered via an on-body injector (OBI). With the phase 3 IRAKLIA trial demonstrating noninferiority to intravenous administration—and significantly higher patient satisfaction—this technology represents a pivotal shift in multiple myeloma care. Dr Ailawadhi breaks down: ✅The Tech: How the enFuse OBI system enhances patient comfort and frees up clinical resources. ✅The Data: Why the IRAKLIA trial findings are a "game changer" for efficacy and safety. ✅The Future: Could this be the bridge to home administration in the US? Read the full analysis here (requires sign-up): https://hubs.li/Q04dfh1p0

Small cell lung cancer (SCLC) remains one of the most aggressive malignancies we face. It is fast-moving, complex, and requires a highly nuanced approach to radiation therapy. In this episode of The OncoloGIST, host Sabrina Serani is joined by radiation oncologist Dr Raj Singh for a deep dive into the changing SCLC therapeutic landscape. We move beyond the basics to tackle the questions currently defining clinical practice: The Debate: Is twice-daily fractionation still the gold standard? The Data: How the landmark ADRIATIC trial is reshaping our treatment protocols. The Workflow: Breaking down the logistical challenges of early radiation integration and managing competing risks in extensive-stage disease. The Future: The expanding role of radiosurgery in brain metastases. Whether you are a medical oncologist, radiation oncologist, or a trainee navigating this space, this conversation offers a practical, forward-looking perspective on how to optimize patient outcomes. Watch the full episode here: https://hubs.li/Q04dbmnj0